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Background: Heterogeneous ventilation in lungs of individuals with allergies, cigarette smokers, asthmatics and
chronic obstructive pulmonary disease (COPD) patients has been demonstrated using imaging modalities such as
positron emission tomography (PET), magnetic resonance imaging (MRI) and single-photon emission computed
tomography (SPECT). These individuals suffer from narrow and/or closed airways to various extents. By calculating
regional heterogeneity in lung ventilation SPECT images as the coefficient of variation (CV) in small elements of the
lung, heterogeneity maps and CV-density curves can be generated and used to quantitatively measure heterogeneity.
This work explores the potential to use such measurements to detect mild ventilation heterogeneities in lung-healthy
subjects.
Method: Fourteen healthy subjects without documented lung disease or respiratory symptoms, and two patients with
documented airway disease, inhaled on average approximately 90 MBq 99mTc-Technegas immediately prior to the
20-min SPECT acquisition. Variation in activity uptake between subjects was compensated for in resulting CV values.
The area under the compensated CV density curve (AUC), for CV values greater than a threshold value CVT, AUC(CV >
CVT), was used as the measure of ventilation heterogeneity.
Results: Patients with lung function abnormalities, according to lung function tests, generated higher AUC(CV > 20%)
values compared to healthy subjects (p = 0.006). Strong linear correlations with the AUC(CV > 20%) values were found
for age (p = 0.006) and height (p = 0.001). These demonstrated that ventilation heterogeneities increased with age and
that they depend on lung size. Strong linear correlations were found for the lung function value related to indices of
airway closure/air trapping, residual volume/total lung capacity (RV/TLC; p = 0.009), and diffusion capacity of the lung
for carbon monoxide adjusted for haemoglobin concentration in the blood (DLCOc; p = 0.009), a value partly related to
supposed ventilation/perfusion mismatch. These findings support the association between conventional lung function
tests and the AUC(CV > 20%) value.
Conclusions: Among the healthy subjects, there is a group with increased AUC(CV > 20%) values, but with normal
lung function tests, which implies that it might be possible to differentiate ventilation heterogeneities earlier in a
disease process than by lung function tests.
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Single-photon emission computed tomography (SPECT)
is increasingly used as a tool in respiratory research and
clinical application. Quantitative lung SPECT has been
shown to be useful for assessment of regional severity of
emphysema [1,2], aerosol deposition and clearance [3],
ventilation and perfusion ratios [2,4], early radiation-
induced lung injury [5], regional perfusion and ventila-
tion [6,7], and of ventilation heterogeneity [8].
Heterogeneous, uneven or patchy ventilation in the
lungs of individuals with allergies, cigarette smokers, asth-
matics and COPD patients has been demonstrated using
various imaging techniques such as positron emission
tomography (PET), magnetic resonance imaging (MRI)
and SPECT [9-15]. These patients suffer from narrow
and/or closed airways by varying degrees. Narrowing of
the airways is caused by inflammation, secretions and the
shortening of muscle fibres around the bronchial walls,
which obstructs airflow. Emami et al. [13] showed that
asymptomatic smokers had a more heterogeneous ventila-
tion distribution compared to healthy non-smokers.
Patchiness can be caused by narrowing of both larger and
smaller airways. Sovijarvi et al. [14] suggested that al-
though larger asthmatic airways are dilated by isoprenaline
inhalations, residual bronchial obstruction may still re-
main in some smaller airways, maintaining a heteroge-
neous distribution. Furthermore, Tgavalekos et al. [9]
concluded that the heterogeneous and patchy distribution
of ventilation in asthma patients is a manifestation of the
complex behaviour of the airway system, rather than the
independent behaviour of individual airways. Closure of
the airways by air trapping occurs when the small airways,
the bronchioles, collapse. According to Ozer et al. [16], air
trapping can be present even before pulmonary function
tests reveal abnormal results, or pulmonary symptoms be-
come apparent. Possible causes of air trapping are aging,
smoking and various obstructive diseases such as asthma
[11,16]. The severity of air trapping has been shown to in-
crease with age and smoking [17].
Regional heterogeneity in lung ventilation SPECT im-
ages may be determined by calculating the coefficient of
variation (CV) in small elements of the lung [8,18]. Het-
erogeneity maps and density curves can then be generated
based on the CV values. This method was used in earlier
work, whereby density curves were evaluated using our
proposed CVT method [8]. Using the revised method, the
proportion of CV values greater than a threshold value
CVT may be determined. The purpose of the CVT-method
is to discriminate between activity distributions in the
lungs of healthy subjects and subjects with affected venti-
lation. The method has been shown to be capable of iden-
tifying simulated mild COPD in an anthropomorphic
phantom, and to differentiate patients with severe COPD
from healthy subjects. The next step is to evaluate theability of the CVT method to detect genuine abnormalities
in subjects who are ‘borderline normal’, according to lung
function tests. Since the outcome of a lung function test is
a summation of the status of the whole lung, quite signifi-
cant changes in lung function may occur before a devi-
ation from the norm can be identified. A method that can
reliably detect lung abnormalities earlier than lung func-
tion tests would therefore be beneficial.
This work explores the potential advantages of quantita-
tive heterogeneity measurements by performing a pilot
study of the CV measurements with healthy human sub-
jects, i.e. those without documented lung disease, respira-
tory symptoms or lung function abnormalities. The
outcome is discussed in relation to gender, age, lung size,
subtle findings on lung function tests and reported aller-
gies, and smoking history.
Methods
Human subjects
Fourteen human subjects were included who were without
documented lung disease or respiratory symptoms, and
who were more than 40 years old. The 14 subjects were
examined by lung SPECT and lung function tests at the
Department of Clinical Physiology, Linkoping University
Hospital during 2012 to 2013. The subjects were also
asked to fill in a health questionnaire. In addition, two pa-
tients with documented airway disease or pulmonary
symptoms underwent the same examination procedure
(referred to as P1 and P2 in Table 1). P1 suffered from
asthma and homozygote alfa-1-antitrypsin deficiency and
P2 had advanced COPD with emphysema, according to
both lung function tests and high-resolution computed
tomography (HRCT). Gender, age, height, weight, body
mass index (BMI), smoking status, history of allergy and
the result of lung function tests for these 16 subjects are
presented in Tables 1 and 2. All subjects were informed
and written consent was obtained. The regional Ethics
Review Board in Linkoping approved the study protocol.
Health questionnaire
The questionnaire covered pulmonary symptoms, smok-
ing history, history of health checks and hospitalisations,
allergies, hypersensitivity and medications.
Lung function tests
The lung function tests consisted of:
 Dynamic flow rate and static lung volume
measurements before and after inhalation of
bronchodilator (Salbutamol, 1.6 alt 0.8 mg):
○ FEV1: forced expiratory volume over 1 s
○ FVC: forced vital capacity
○ RV: residual volume
○ TLC: total lung capacity
























S1 M 49 191 82 22.5 Never No Yesd Upperj Nom 76 29
S2 M 49 185 77 22.5 Never No Yese Upperj No 77 30
S3 M 50 190 85 23.5 Never No Yesf Upperj No 78 30
S4 M 48 187 75 21.4 Never Yesa No - No 77 31
S5 M 50 178 72 22.7 Never No No - No 78 33
S6 M 69 181 100 30.5 Never Yesa No - No 78 34
S7 M 60 188 85 24.0 Current - No - Non 78 34
S8 F 65 177 66 21.1 Current - Yesg Lowerk No 80 34
S9 F 51 170 85 29.4 Never Yesa No - No 78 36
S10 M 75 175 92 30.0 Never No Yesh Upperj Noo 79 39
S11 M 73 175 77 24.9 Ex-smoker - No - No 80 41
S12 F 67 172 78 26.4 Never Yesb No - Nop 83 47
S13 F 67 167 79 28.3 Never Yesc Yesi Lowerl Noq 84 47
P1 M 55 176 85 27.4 Never - - - Yeso,r,s 83 43
P2 M 81 167 58 20.8 Ex-smoker - - - Yes 90 61
a20 years during childhood; b14 years during childhood and occupational; c10 years occupational; dgrass, pollen and dust; efur animals and grass; ffur animals and
pollen; gstrong fragrances; hcat and chocolate; ibirch pollen, timothy, grass, nuts, penicillin and sulfonamide; jrhinoconjunctivitis; kcough; lshortness of breath;
msubject medicated with nasal spray of Budesonide at time of examination; nbased on FEV1, FVC, FEV1/FVC, TLC and RV without bronchodilation; obased on
DLCOc before and FEV1, FVC, FEV1/FVC, TLC and RV after bronchodilation; ppossible early signs of emphysema based on a reduced DLCOc value (see Table 2) and
an elevated haemoglobin concentration in the blood; qbased on FEV1, FVC and FEV1/FVC without bronchodilation; rsubject medicated with inhalation of
Budesonide and Formoterol in combination at time of examination; smoderate obstruction and signs of reversibility.
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RV/TLC were determined.
 DLCOc: gas exchange across alveolar capillary
membrane (without bronchodilator). This is
measured by means of single breath test of diffusion
capacity for carbon monoxide adjusted for
haemoglobin concentration in the blood.
The measurements were performed according to the
ATS criteria [19-21]. The measurements were performed
and documented using a Jaeger MasterScreen (Body and
Diffusion) (CareFusion Germany 234 GmbH, Hoechberg,
Germany). A nose clip was used during all lung function











S10 125 119 107 - -
S11 114 114 102 103 96
S12 89 91 98 106 128
S13 91 94 98 - -
P1 79 107 74 - -
P2 40 57 72 132 214
Subjects with AUC(CV > 20%) values of more than 37%. Subjects S10 to S13 are list
over one second; FVC, forced vital capacity; TLC, total lung capacity; RV, residual vo
haemoglobin concentration in the blood. Lung function values without bronchodilaage and height were used [22,23], according to clinical
routine. In Table 2, lung function values recorded with-
out previous bronchodilation are given as percentage of
predicted reference values, e.g. FEV1 % predicted. One
experienced physician evaluated the data of the lung
function tests, blinded to the results of this quantitative
SPECT-study and also blinded to the identity of the sub-
jects and patients.
Ventilation SPECT, acquisition and reconstruction
The lung SPECT examinations were performed as de-
scribed previously [8]. Briefly, starting from functional
residual capacity, the subjects took a deep inhale of






of FEV1 after bronchodilator
AUC(CV >
20%) [%]
- 85 No 39
93 95 No 41
120 76 No 47
- - - 47
- 85 Yes 43
165 38 No 61
ed in order of increasing AUC(CV > 20%) value. FEV1, forced expiratory volume
lume; DLCOc, single breath dilution carbon monoxide test adjusted for
tor use are reported as percentage of predicted reference values (% pred).
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average, approximately 90 MBq of Technegas was depos-
ited in the lungs of each subject. The subjects inhaled the
gas in a supine position, and a ventilation SPECT was
immediately acquired in the same position, using a low-
energy high-resolution collimator on a GE Infinia
(Milwaukee, WI, USA). A low-dose computed tomog-
raphy (CT) scan was also performed in the same position
using the X-ray source and detector mounted on the
gamma camera. The effective dose for this protocol is esti-
mated to be 3.1 mSv (1.3 mSv for SPECT [24] and 2 mSv
for CT), which required a total acquisition time of 25 min.
Three-dimensional (3D) SPECT images were recon-
structed using the iterative ordered subset expectation
maximisation reconstruction software developed at Johns
Hopkins University, Baltimore, MD, USA. The reconstruc-
tion included correction for attenuation, scatter and colli-
mator detector response (CDR). The CT scans were used
for attenuation correction. Scatter correction was per-
formed using the effective source scatter estimation (ESSE)
[25,26]. An analytic, geometrical model for CDR compensa-
tion was used. Reconstructions were performed using four
iterations and 16 subsets [27]. The side length of the cubic
voxels in the reconstructed image was 3.45 mm. The recon-
structed images were post-filtered using a Butterworth filter
[28] with a cut-off frequency of 0.6 cm−1 and a power of 6.
Defining the extension of the lung and sub-volumes
To define the extension of the lung, a semi-automated
procedure was used for each subject based on the individ-
ual CT acquisition and an empirical linear attenuation co-
efficient threshold value of 0.12 cm−1. This segmented
lung volume was used for analysis unless otherwise stated.
An inner volume of interest was created by eroding the
outer boundary of the segmented lung by three voxels
[29]. The outer volume of interest was created by subtract-
ing the inner volume from the original, segmented lung.
Method for analysis of heterogeneities
The density curve and the CV-based measure
The density curve method applied has been described in
detail previously [8]. Briefly, the coefficient of variation
(CV) is calculated for overlapping cubic volumes (1 cm3)
covering the 3D reconstructed activity distribution in
the segmented lung, creating a 3D CV matrix. The vari-
ation of activity uptake between subjects was compen-
sated for in the calculation of CV values, based on the
assumption that each subject had a healthy lung volume
and that the healthy volumes in all subjects should gen-
erate equivalent CV values (for a detailed description,
see the Appendix). The compensated CV values of the
matrix were plotted as density curves (normalised CV
distributions) with an area under the curve (AUC) of
100%, for each subject. A CV-threshold value wasdefined, CVT. The area under the density curve (AUC)
for CV values greater than the threshold value was then
calculated for all subjects, i.e. AUC(CV > CVT).
Statistics
Linear regression analysis was used to determine associa-
tions between AUC(CV >CVT) and the explanatory vari-
ables age, height, BMI, smoking status and allergy,
respectively. The assumptions for linear regression analysis
were verified (normality and constant variance among the
residuals). Linear correlations were also determined in the
same way for AUC(CV >CVT) and each of the lung func-
tion values recorded in healthy subjects: RV, RV/TLC and
DLCOc. Lung function values recorded without previous
bronchodilation and expressed in non-normalised values, i.
e. not % predicted, were used to compare with AUC(CVT)
data, since lung SPECT examinations were performed and
expressed accordingly. Furthermore, the relationship be-
tween lung function abnormalities (yes or no, according to
interpreted lung function tests) and the AUC(CV > CVT)
value was assessed in the same manner; but in this case,
both healthy subjects and patients were included.
Results
The 13 subjects (S1 to S13) included in the analysis are
listed in Table 1, together with corresponding values for
patient P1 and P2. One subject, who did not successfully
inhale an adequate amount of Technegas, was excluded.
In general, the youngest and tallest non-smokers (who
never smoked) in the study generated the lowest AUC
(CV >CVT) values (S1 to S4). Thereafter, the AUC(CV >
CVT) value increased with age and decreasing height. Fi-
nally, the highest AUC(CV > CVT) values were found in
the subject with signs of lung function abnormalities (sub-
ject S12) and in the two patients (P1 and P2) who had
documented lung diseases.
The density curves for subjects S1 to S4 were plotted in
Figure 1a. A mean density curve was subsequently con-
structed based on these subjects (hereafter called the
mean curve). Subjects S1 to S4 were well represented by
the mean curve. These subjects were all males in the same
age (48 to 50 years), height (185 to 191 cm) and weight
(75 to 85 kg) brackets. All had never smoked, and had
normal lung function. Subjects S1 to S3 reported aller-
gies to dust, grass, birch pollen or fur animals, but with
manifestations in the upper respiratory tract only (i.e.
rhinitis with or without conjunctivitis). Subject S4 re-
ported no allergies. Subject S1 had symptoms of rhinitis,
and was medicated with nasal spray of Budesonide, at
the time of examination. Based on the mean curve and
the CVT method from earlier studies [8,27], we defined
CVT = 9.5% as the mode of the mean curve, and calcu-
lated and listed the AUC(CV > 9.5%) for all subjects and
patients in Table 1.
Figure 1 Density curves for low AUC(CV > 20%) subjects and patients (P1 and P2). (a) Density curves corresponding to subject S1 (solid
line), S2 (dotted line), S3 (dashed line) and S4 (dashed-dotted line), together with their constructed mean curve in green. (b) Density curves of
patient P1 (dotted line) and P2 (dashed line) together with the mean curve (green line). AUC for CV values greater than 20%, i.e. AUC(CV > 20%),
for the mean curve is marked as light green.
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stantially different from the mean curve, as shown in
Figure 1b, especially for patient P2, with advanced COPD.
The density curve of P1, a patient with documented air-
way disease, is associated with a larger proportion of high
CV values compared to the mean curve, but is not as pro-
nounced as the density curve of P2. Based on Figure 1b,
an additional threshold value was defined, CVT = 20%, ap-
proximately at the point where the patient curves and the
mean curve intersect. AUC(CV > 20%) values were calcu-
lated for all subjects and patients, and are listed in Table 1.
AUC(CV > 20%) for the mean curve is marked as light
green in Figure 1b. Since AUC(CV > 20%) resulted in a
favourably larger range (29% to 47%) compared to the
range of AUC(CV > 9.5%) values (76% to 84%) for the in-
cluded healthy subjects, CVT = 20% was used hereafter.
Listing the subjects in order of increasing AUC(CV >
9.5%) value would introduce shifts between adjacent sub-
jects in Table 1, which implies the chosen threshold has
only a minor affect on outcome.
The remaining healthy subjects were divided into two
groups, S5 to S9 and S10 to 13, depending on their
density curves, which are shown in Figure 2a,b, respect-
ively. The density curves of subjects S5 to S9 exhibited
small differences from the mean curve. This group con-
sisted of subjects with a broader range of characteristics
compared to subjects S1 to S4; males and females, aged
50 to 69 years, with a height range of 170 to 188 cm and
a weight range of 66 to 100 kg. All subjects in this group
had normal lung function, but were current smokers or
never smoked and were with or without an allergy. Sub-
ject S8 reported hypersensitivity to nickel and strong fra-
grances. The latter associated with symptoms from the
lower respiratory tract (coughing), but at the time of
examination, no such symptoms occurred. In contrast,
the density curves of subjects S10 to S13 displayed larger
differences from the mean curve. This group was alsomore heterogeneous regarding their characteristics and
consisted of males and females, aged 67 to 75 years, with
a height range of 167 to 175 cm and a weight range of
77 to 92 kg. They were ex-smokers or had never smoked
and were with or without stated allergies. None of these
subjects with reported allergies had symptoms at the
time of examination. The results of thorough lung func-
tion tests were interpreted as normal, with or without
early signs of lung function abnormalities. Results of
lung function testing of subjects S10 to S13 and P1 and
P2 are presented in Table 2.
Significantly higher AUC(CV > 20%) values were found
for subjects with abnormal lung function tests compared
to those with normal test results (p = 0.006). Strong linear
correlations were found between the AUC(CV > 20%)
value and height and age, respectively, for the 13 healthy
subjects, listed in Table 3 and plotted in Figure 3. Sixty-
seven percent (see r2 in Table 3) of the variation in AUC
(CV > 20%) can be explained by height and 51% by age.
The correlations were statistically significant between
AUC(CV > 20%) and both height (p = 0.001) and age (p =
0.006). For each centimetre increase in height, AUC(CV >
20%) decreased by an average of 0.61 (0.33 to 0.90) units
(see B in Table 3). For each additional year of life, the
AUC(CV > 20%) value increased by an average of 0.41
(0.15 to 0.68) units. The lung function values RV/TLC and
DLCOc were also found to have strong linear correlations
with AUC(CV > 20%), also with high statistical significance
(p = 0.009) (see Table 3 and Figure 3c,d). Ten and 11 of
the healthy subjects (in Table 1) had DLCOc and RV/
TLC, respectively, measured before treatment with bron-
chodilator, and were therefore included in the analysis.
Males on average had lower AUC(CV > 20%) values than
females (p = 0.034). No statistically significant differences
were found between subjects who never smoked, current
smokers and ex-smokers. However, there was a tendency
for ex-smokers to have higher AUC(CV > 20%) values
Figure 2 Density curves for intermediate-AUC(CV > 20%) subjects (S5-S9) and high-AUC(CV > 20%) subjects (S10 to S13). (a) Five
density curves corresponding to intermediate AUC(CV > 20%) values; subject S5 (solid line), S6 (dotted line), S7 (dashed line), S8 (dashed-dotted
line) and S9 (dashed-dotted-dotted line), together with the mean curve (green line). (b) Four density curves corresponding to the highest AUC
(CV > 20%) values of subjects; subject S10 (solid line), S11 (dotted line), S12 (dashed-dotted line) and S13 (dashed line), together with the mean
curve (green line).
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ference between healthy subjects with or without stated al-
lergies was observed, but in a sub-group analysis among
subjects with allergies, a tendency of higher AUC(CV >
20%) values was found for subjects with symptoms from
the lower respiratory tract, compared to the upper respira-
tory tract. No correlation with AUC(CV > 20%) was found
for BMI or RV.
One of the strengths of image-based methods is the abil-
ity to visualise where quantified heterogeneities are situ-
ated. To illustrate where different CV values are generally
positioned, we show CV values below 9.5% as green, be-
tween 9.5% and 20% as yellow and above 20% in red, for
two subjects (Figure 4). Areas in green and yellow are in
the peak of the mean curve and are found in the centre of
the lung for both subjects. Due to the moderate spatial
resolution of the gamma camera system, (false) high CV
values are generated in the periphery of the lung of a
healthy subject (the periphery or edge effect [8]). There-
fore, red areas are found in the periphery of the lungs of
both subjects, but a larger proportion is found in subject
S12 compared to subject S1.Table 3 Univariate linear regression analysis
Variables r B with 95% CI r2 p n
Height (cm) −0.82 −61 (−90,−33) 0.67 0.001 13
DLCOc (mmol min−1 kPa−1) −0.77 −1.9 (−3.2, −0.6) 0.60 0.009 10
RV/TLC (%) 0.74 0.57 (0.18, 0.97) 0.55 0.009 11
Age (years) 0.72 0.41 (0.15,0.68) 0.51 0.006 13
Analysis of the correlation of the AUC(CV > 20%) value with height, age and
lung volumes related to closed airways and air trapping (RV/TLC) and
ventilation/perfusion mismatch (DLCOc), respectively. Only lung function
values obtained without bronchodilator of healthy subjects were used in the
analysis. The results are listed in order of decreasing absolute value of the
Pearson's correlation coefficient, r. B is the gradient of the regression line,
given together with lower and upper boundary of the 95% confidence interval.
The coefficient of determination, r2, the associated significance value, p, and the
number of healthy subjects, n, included in the calculations are also included.To illustrate the differences in the CV distributions of
the inner and outer volume of the segmented lung for
subject S12, we created two density curves based on each
sub-volume. For comparison, the same procedure was ap-
plied to the mean density curve (Figure 5). The main dif-
ference in the CV distributions of the mean curve for
subjects S1 to S4 and S12 is a shift of CV values in the
outer volume, but not in the inner volume. For subject
S12, the outer volume is 60% of the total volume, and
50%, 51%, 53% and 56% for the subjects used to calculate
the mean curve.
Discussion
In this study, we used a previously reported CVT method
[8] and introduced an adaptation that compensates for
subject-to-subject variation, making the CV values from
healthy lung volumes of different subjects comparable. This
adaptation makes it possible to better evaluate the ability of
the CVT method to discriminate between subjects with less
pronounced differences in ventilation heterogeneity. In a
previous study, we showed that significantly higher AUC
(>mode) values resulted from patients with severe COPD,
compared to healthy subjects who had never smoked [8].
Therefore, we expect subjects with gradually less altered
lung function to generate gradually lower AUC(CV > 20%)
values. We found the result of this pilot study very promis-
ing since the list of subjects placed in order of increasing
AUC(CV > 20%) value (Table 1), calculated with the im-
proved method, supports this idea.
In this study, we have shown that patients (P1 and P2)
generated significant higher AUC(CV > 20%) values com-
pared to healthy subjects (S1 to S13) (p = 0.006), which is
consistent with the result of a previous study [8]. Subjects
S10 to S13 showed deviating density curves compared
to the mean curve (calculated from subjects S1 to S4),
and consequently higher AUC(CV > 20%) values, without
Figure 3 Correlation between AUC(CV > 20%) and (a) height, (b) age, (c) DLCOc and (d) RV/TLC. For subjects (S1 to S13). Spread of data to
the regression line is shown for each parameter in (a-d).
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that it might be possible to detect ventilation heterogene-
ities by the AUC(CVT) method earlier in a disease process
than by lung function tests. The fact that one of the 13
healthy subjects, who exhibited possible early signs of em-
physema (S12), also showed abnormal AUC(CV > 20%),
tends to support the notion that the AUC(CVT) method is
more sensitive to minor pulmonary abnormalities than
conventional lung function tests.
Despite the low sample size in this pilot study, a group
of subjects was identified who never smoked and were
of the same gender (male), age bracket (48 to 50 years)
and physique (height 185 to 191 cm and weight 75 to
85 kg), namely subjects S1 to S4 (Table 1). These sub-
jects displayed the lowest AUC(CV > 20%) values. Three
of them (S1 to S3) had allergies with symptoms from theFigure 4 Coronal slices of CV matrices for subjects S1 and S12.
CV slices with CV values below 9.5% in green, between 9.5% and
20% in yellow and above 20% in red for subject S1 to the left and
subject S12 to the right.nose only, i.e. the upper respiratory tract, occurring sea-
sonally or after allergen exposure. Therefore, we assume
that the reported allergies had no impact on the out-
come of the lung function tests or lung SPECT examina-
tions. Subjects S2 and S3 had no symptoms at the time
of examination; however, S1 suffered from persistent but
subtle symptoms (rhinitis) and this was treated with
nasal spray of a corticosteroid at the time of spirometry
and lung SPECT examinations.
Lung function values are normalised to a reference
distribution depending on gender, age and height. This
study has shown that AUC(CV > 20%) also has a depend-
ence on age and height.
Aging is associated with increased chest wall stiffness
[30] and an increase in residual volume, which reduces the
vital capacity. The effect of aging on lung tissue is an in-
crease in lung compliance, which results in reduced paren-
chymal recoil on the airways, reducing airway calibre and
increasing airway closure and gas trapping [16,17,30].
Such changes would result in a more uneven ventilation
distribution in an older, healthy subject, compared to a
younger, healthy one, which corresponds to an increasing
AUC(CV > 20%) value with age. The proposed method
confirms this expected increase in AUC(CV > 20%) with
age, compatible with the notion of age-dependent alter-
ations of lung compliance (see Table 3).
The geometrical resolution of the SPECT system is
limited; and therefore, high CV values will always be
found in the periphery of the lung, even in subjects with
a healthy lung (Figure 4). This periphery effect results in
Figure 5 Entire, inner, peripheral density curves for mean (S1 to S4) and S12, and coronal inner/peripheral contours. The segmented
lung divided into inner and outer volumes, (a) the mean density curve (solid green line), and its inner (light green area), and outer (dark green area)
volume components, as well as the S12 density curve (solid black line), and its inner (black dashed line) and outer (black dash-dotted line) volume
components. (b) Coronal slices of the CV matrix for S1 (left, used to calculate the mean) and S12 (right). Contours indicate the inner and outer volumes.
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the peripheral volume of the small lungs is a larger pro-
portion of the total lung volume, compared to the larger
lungs (cf. Figure 4). Therefore, small lungs would gener-
ate a larger proportion of high AUC(CV > 20%) values
compared to larger lungs. Generally, a short person has
smaller lungs than that of a taller person. This study
demonstrated the expected decrease of AUC(CV > 20%)
values with increasing height (see Table 3). Since the
lung SPECT examination is performed with the subject
in supine position, the volume of the lung should also
depend on how much pressure is placed on the dia-
phragm by the abdomen. This effect would be greater
for subjects with a larger BMI. This study, however,
found no BMI dependence.
Generally, as in this study, males are taller than females,
which might explain why, on average, males resulted in
lower AUC(CV > 20%) values than females. The possibility
to analyse the outer part of the lungs separately makes it
possible to discriminate between healthy and non-healthy
distributions in this region (see Figures 4 and 5).
We found a strong correlation between AUC(CV >
20%) and RV/TLC, as well as between AUC(CV > 20%)
and DLCOc (see Table 3). The former supports the value
of measuring heterogeneities in ventilation lung SPECT
images, since this lung function parameter measure the
volume with closed airways and air trapping (RV/TLC).
The fact that all CV-density curves are normalised to
generate the same total area under the curve (100%),
might explain why RV/TLC, but not RV per se, showed
a strong association with AUC(CV > 20%). One might
argue that these correlation studies would speak against
the value of lung-SPECT measurements in comparison
to lung function testing. However, in this context, it is
important to note that all except one of the subjects
(S12) was considered fully ‘normal’ by a physician, whois a recognised expert on lung function tests. Further-
more, lung SPECT provides the possibility to visualise
the location of the malfunctioning volumes in the lungs
(see Figures 4 and 5), unlike lung function tests.
Smoking may lead to increased sputum production, de-
creased ciliary movement, inflammation of both large and
small airways, constriction of the encircling smooth
muscle and collapsed airways, resulting in obstructed air-
ways and air trapping [16,17]. Also, involuntary exposure
of non-smokers to tobacco smoke has a negative effect on
the lungs, especially for exposed children [31]. Such
changes would result in a more uneven ventilation distri-
bution compared to healthy subjects who never smoked
[13] and therefore an increased AUC(CV > 20%) value. In
this small pilot study, we found a tendency of ex-smokers
to have a higher AUC(CV > 20%) value than subjects who
never smoked and current smokers.
Allergies with symptoms in the upper respiratory tract,
such as allergic rhinitis, is not expected to affect the
AUC(CV > 20%) value, while allergies with symptoms
in the lower respiratory tract may well, at least during
allergy season or after allergen exposure. According
to Hens and Hellings, the increasing recognition over
recent decades that allergic rhinitis and allergic asthma
frequently co-exist has led to the concept of ‘united
airways’, and that these disorders are manifestations
of the same disease expressed to a greater or lesser
extent in either the upper or the lower airways [32].
In some patients, rhinitis predominates and asthma is
undiagnosed or sub-clinical; in others, the situation is
reversed, while in many cases, both are clinically
expressed [33]. In a sub-group analysis among subjects
with allergies, a tendency of higher AUC(CV > 20%)
values was found for subjects with symptoms from the
lower respiratory tract compared to that of the upper
respiratory tract.
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halation, but subsequent imaging was performed with the
subject breathing normally in supine position. This resulted
in a higher activity region in the posterior parts of the lung;
the so called ‘rind effect’, caused by gravity compressing the
posterior airways that increased the measured CV values in
this region. Schembri et al. [34] noted that the ‘rind effect’
was reduced when imaging was done in prone position and
with tidal breathing during ventilation. Inhaling the Tech-
negas as a normal breath (with a 5-s breath-hold) might
therefore reduce this ‘rind effect’ and thus its effect on the
CV values. No attempt was made to exclude possible ‘hot
spots’ caused by turbulence in the conducting airways, since
‘hot spots’ are rare in healthy subjects.
One limitation of this study is the low number of par-
ticipants, and consequently a single observation had a
large impact on the linear correlation. With a larger
number of subjects with different smoking histories and
subjects with allergy symptoms from both the upper and
lower respiratory tract, the tendencies found in this pilot
study might find statistical significance. The information
of possible air trapping and emphysema from HRCT
could have been beneficial for this study. The relatively
high effective dose from this procedure prevented us
from performing HRCT on the healthy subjects.
Conclusion
Using the adapted CVT method, with the newly imple-
mented compensation technique, we showed that patients
with lung function abnormalities detected by conventional
lung function tests generated significantly higher AUC(CV
> 20%) values compared to healthy subjects with normal
lung function tests (p = 0.006). Increased AUC(CV > 20%)
values were also detected among subjects who had normal
lung function tests but indications of conditions associated
with ventilation disturbances. The results suggest that our
present SPECT method has the capacity to identify minorFigure 6 Density curves, uncompensated for subjects and simulated
examined healthy subjects: S1 to S4 (green) and S5 to S13 (black), togethe
patients (red). (b) Density curves based on the phantom lung activity distri
partly heterogeneous (dotted black line) (with equal activity concentrationlung function abnormalities earlier in a disease process than
conventional lung function tests. Our positive findings have
provided the motivation to extend this pilot study to a full
study with a larger number of subjects.Appendix
The compensation method
Our main objective was to adapt an existing method,
which is based on the coefficient of variation, CV, to be
able to differentiate between varying grades of ventila-
tion heterogeneities in healthy human subjects, accord-
ing to lung function tests. In both this study and earlier
work [8], it was found that for healthy subjects, the posi-
tioning of the calculated CV density curves on the CV
axis varied to such an extent that it was impossible to
discriminate between small heterogeneity variations be-
tween subjects (see Figure 6a). Monte Carlo simulations
and various predefined activity distributions in a phantom
lung were used to analyse properties of the density curve.
We tested the density curves for different types of distri-
butions, based on either an entirely uniform (homoge-
neous) activity distribution, or a partly uniform/partly
heterogeneous activity distribution. We noticed that they
had the same starting point on the CV axis and the same
mode value of their density peaks, provided that the num-
ber of 99mTc particles per unit volume in the uniform
(‘healthy’) parts of the lungs was the same (see Figure 6b).
A simulated density curve of an activity distribution with
no uniform regions does not show this pattern (see red
line in Figure 6b). The density curves in Figure 6b also
illustrate that the low CV values, positioned in the dens-
ity peaks of the ‘healthy’ and ‘partly healthy’ lungs (black
lines in Figure 6b) correspond to the uniform part of
the activity distributions, while the heterogeneous parts
of the activity distributions are represented by higher
CV values.for phantom activity distributions. (a) Density curves of the 14
r with the excluded subject (black dash-dott-dott-dotted) and the two
butions that were entirely uniform (solid black line), partly uniform/
in the healthy, uniform regions), and entirely heterogeneous (red line).
Figure 7 Density curves for a phantom lung with
heterogeneities, with decreasing activity levels. Density curves
based on three decreasing average number of 99mTc particles per
unit volume are shown, with the highest (left solid line), middle
(centre dotted line) and the lowest (right dashed line).
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on the number of 99mTc particles per unit volume (activity
concentration). Density curves for the central voxels (with
the periphery effect excluded) of two uniform activity
distributions with different concentration levels can be
transformed to the same shape and position on the CV
axis as that corresponding to the highest activity concen-
tration. This is done by multiplying the CV values of the
density curve for the lower activity concentration by the
ratio of the mode values of the respective density curves
(see Equation 1).
Ahigh 99mTc concentration
¼ Alow 99mTc concentration :
Mhigh 99mTc concentration
Mlow 99mTc concentration
ð1ÞFigure 8 Density curves before and after compensation for (a) S13 an
curves are shown for before (black dashed line), after (black solid line) com
line). The subject in (b) was excluded due to a relatively low concentrationwhere A is the vector of CV values generating the dens-
ity curve and M is the mode value. The indices ‘high’ and
‘low’ indicate the level of activity concentration.
A phantom lung was used with spherical regions of re-
duced activity, compared to the surroundings [8]. The ori-
ginal density curves are asymmetric, with a distinct peak
at low CV values (corresponding to the healthy parts of
the lung) and a tail at higher CV values (corresponding to
the heterogeneities). By reducing the activity, the density
curve becomes a symmetric bell (Figure 7). This change in
shape is caused by the gradual ‘loss of information’ by the
SPECT system due to the increase in statistical noise. If
Equation 1 were applied to transform the density curve
based on a low to a higher average particle concentration,
it would not fully succeed. This is because the tail end,
containing the heterogeneity information, cannot be re-
stored (see Figure 7); the transformed CV distribution
would look like that of a uniform activity distribution. Fur-
thermore, when transforming a density curve based on a
high to a lower average particle concentration, the result-
ing density curve would contain too long a tail of CV
values. Therefore, any transformation has to be performed
with caution.
The compensation method we propose is an attempt to
compensate for subject-to-subject variation in activity up-
take, and is based on the observations described above.
The basic assumption is that each subject has a healthy
lung volume that is large enough to generate a distinct
peak in the density curve. Since the aim of the study was
to find mild ventilation heterogeneities in subjects with
normal lung function, according to lung function tests, we
assume that subjects with no healthy lung regions
are rare.
The compensation procedure was performed in two
steps. First, a shift of all density curves was made so that
the left flank of the density curves passed through a
well-chosen point in the plot, namely a density of 0.5%
at 3 CV% (hereafter called the fix point). This point wasd (b) S (excluded); both with mean (S1 to S4). For both subjects,
pensation, together with the compensated mean curve (green solid
of Tc particles per unit volume in the lung.
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http://www.ejnmmires.com/content/4/1/39chosen because many of the uncompensated density
curves passed close to this point (Figure 6a). A hypothet-
ical healthy subject with a density curve resembling the
mean curve, as defined in the results of this study, that
intersects the fixed point is referred to here as the norm.
This curve needs no compensation. Secondly, a trans-
formation of the shape of the density curves was
performed according to Equation 2.
Acompensated ¼ Ashifted⋅ 9:59:5‐shift ð2Þ
where Acompensated is the vector of CV values generat-
ing the compensated density curve and Ashifted is the
shifted CV vector. The mode value of the mean curve
defined in the ‘Results’ section is 9.5%. The shift is nega-
tive if the subject has a lower activity concentration in
its healthy regions compared to the norm.
Compensations according to Equation 2 result in less
pronounced changes in the shape of the density curve
compared to using Equation 1. The density curves of sub-
ject S13, before and after compensation, are shown in
Figure 8a. In this case, the effect of the compensation was
small. The effect of the compensation can sometimes be
too large, even though we have chosen a compensation
method that has a lower impact on the density curve
compared to that using Equation 1. Therefore, there is a
limiting minimum activity concentration for which the
compensation method is useful. This is illustrated in
Figure 8b. The subject was excluded from the study due to a
relatively low concentration of 99mTc particles in the lungs.
When the proposed compensation method was applied to
the density function of this subject, the resulting AUC(CV>
20%) value was even lower than that for the subjects repre-
senting the mean curve. This is a misleading result.
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